Patients who explore regenerative medicine for the first time almost always ask the same question early in the process: will my insurance pay for this? The honest answer requires understanding how insurers classify these treatments, how the regulatory environment shapes coverage decisions, and where a small number of exceptions exist. This article walks through each of those areas so you can enter a conversation with your insurance company and your clinic with accurate expectations.
The Current Insurance Landscape for Regenerative Therapy
Why Most Stem Cell Procedures Are Not Covered
Insurance coverage decisions in the United States follow a consistent logic: before a payer agrees to cover a procedure, it typically needs substantial clinical evidence from controlled trials, established billing codes, and in most cases some form of regulatory clearance or approval. Regenerative medicine therapies, including mesenchymal stem cell injections derived from bone marrow or adipose tissue, currently lack FDA approval as drug products for the vast majority of musculoskeletal indications. Because of this, most commercial insurers, Medicare, and Medicaid classify these procedures as experimental or investigational.
The “experimental” label is not a permanent moral judgment. It is a formal classification that reflects where a treatment stands in the evidence cycle. Insurers apply it when clinical trials have not yet produced the volume and quality of data that payers require before they build a procedure into their coverage framework. For stem cell therapy applied to osteoarthritis and musculoskeletal conditions, multiple clinical trials are underway and a growing body of peer-reviewed research exists, but the field has not yet completed the controlled-trial pipeline that changes insurer classification.
What would change this classification? Primarily two things: a large body of randomized controlled trial data demonstrating consistent safety and efficacy across diverse patient populations, and formal FDA approval or clearance for specific indications. As either of those thresholds is met for specific applications, coverage decisions by major payers are likely to shift. The landscape is moving, but it has not moved enough yet for most patients to expect reimbursement for stem cell procedures targeting joints or soft tissue.
FDA Classification and Its Effect on Coverage
The FDA regulates human cells, tissues, and cellular and tissue-based products through a framework commonly referred to as the HCT/P regulations. Within this framework, there is an important distinction between procedures that qualify under what is called Section 361 regulation and those that require a full biologics license application (BLA).
Autologous same-day procedures, in which cells are collected from a patient, minimally processed without substantial manipulation, and re-injected into that same patient during the same clinical encounter, may qualify under the lower-tier regulatory pathway. This pathway does not require FDA pre-market approval in the same way a pharmaceutical drug does. However, qualifying under this pathway does not mean the procedure is FDA-approved in the way that a drug product with a BLA would be. It means it meets specific conditions that allow it to operate without going through the full drug approval process.
This distinction matters for insurance coverage because insurers often look specifically for FDA-approved drug status when evaluating biologics. A procedure that operates lawfully under 361 regulation is not the same as one that has completed the BLA process and received FDA approval. Insurers typically treat procedures in the 361 category as lacking sufficient regulatory endorsement for coverage purposes.
The FDA has also created a Regenerative Medicine Advanced Therapy (RMAT) designation, which is an expedited development and review pathway for regenerative medicine products that show early clinical promise for serious or life-threatening conditions. RMAT designation does not mean approval, but it does accelerate the development timeline. Several cell therapy products have received RMAT designation in recent years. When products that hold RMAT designation eventually receive full approval for specific indications, coverage decisions for those products will likely follow.
The only FDA-approved stem cell products currently available in the United States are hematopoietic progenitor cells derived from umbilical cord blood, approved for disorders affecting the blood-forming system such as leukemia, lymphoma, and sickle cell disease. These are entirely distinct from the mesenchymal stem cell injections used in musculoskeletal regenerative medicine.
What Is Sometimes Covered and What Is Not
PRP Coverage: Varies by Carrier and Condition
Platelet-rich plasma therapy occupies a different regulatory and coverage position than stem cell therapy, and it is worth examining separately. PRP is not FDA-approved as a drug product for musculoskeletal conditions either, but some commercial insurance plans do cover PRP for specific diagnoses under specific circumstances.
Research suggests that some insurers cover PRP for chronic tendinitis, particularly lateral epicondylitis (tennis elbow) and Achilles tendinopathy, when conservative treatments have failed and the clinical documentation supports medical necessity. Wound healing applications for PRP have also received coverage under some policies, particularly for chronic wounds in diabetic patients.
Medicare generally does not cover PRP for musculoskeletal conditions. The program has reviewed the evidence and has not found it sufficient to support a national coverage determination that would open PRP to routine reimbursement for joint or tendon applications. Commercial plans vary considerably. Some Blue Cross Blue Shield regional plans cover PRP for certain ICD-10 diagnosis codes, while others explicitly exclude it. United Healthcare, Aetna, and Cigna each have their own medical policies, and those policies differ by product line and region.
Because of this variability, patients must verify coverage with their specific plan before assuming PRP is either covered or excluded. The most important step is to get any confirmation in writing. A verbal statement from a customer service representative is not the same as a written coverage determination, and verbal statements are not binding in a coverage dispute.
Billing codes also affect coverage outcomes. PRP is often billed under CPT code 86999 or under other unlisted biologic injection codes, and how a plan responds to those codes depends on its internal policies. Clinics and patients alike need to understand which codes will be submitted and how the plan responds to those specific codes before proceeding.
IV Therapy: When Medical Necessity Applies
IV therapy administered for a documented deficiency state may be covered by insurance when medical necessity is clearly established. IV vitamin B12 administered to a patient with confirmed B12 deficiency due to pernicious anemia or malabsorption, for example, may be covered under standard medical benefits. IV iron administered to a patient with iron deficiency anemia when oral supplementation is not tolerated or absorbed may also qualify for coverage.
IV therapy administered for wellness optimization, general energy, immune support, or performance enhancement does not typically meet the definition of a covered medical expense under standard insurance plans. These applications may be genuinely beneficial for some patients, but insurers apply a medical necessity standard, and elective wellness infusions do not meet that standard.
The distinction in documentation matters significantly. A patient with confirmed magnesium deficiency documented by laboratory testing who receives IV magnesium has a more defensible coverage claim than a patient receiving the same infusion as a general wellness measure. Physicians who order IV therapy for documented deficiency states should ensure the documentation clearly reflects the diagnosis, the laboratory findings, and the medical rationale for IV rather than oral supplementation.
Consultation and Diagnostic Imaging
The initial consultation with a physician at a regenerative medicine clinic is typically billable under standard evaluation and management codes (office visit codes) and may be reimbursable by insurance depending on your plan and coverage type. Patients with active insurance should ask the clinic whether it accepts their insurance for the consultation portion, even if the procedures themselves are cash-pay.
Diagnostic imaging ordered as part of a clinical workup for a known condition may also be covered. An MRI of the knee ordered to evaluate suspected osteoarthritis severity may be covered by insurance under your standard diagnostic benefits, even if it is being used to help guide a treatment plan that ultimately involves a non-covered procedure. The coverage applies to the diagnostic purpose, not to the downstream treatment plan.
Where patients sometimes encounter complications is when imaging is ordered specifically for treatment planning in ways that are coded differently from standard diagnostic imaging. Insurers may question coverage if the imaging documentation suggests it was ordered for the purpose of guiding an investigational procedure rather than for standard diagnostic purposes. Physicians should code and document imaging accurately based on the clinical indication.
How Patients Typically Pay
Cash Pay and What That Means for Pricing Transparency
The majority of regenerative medicine clinics operate on a cash-pay basis for stem cell and PRP procedures. This means patients pay directly, without insurance intermediaries. Cash-pay models can offer pricing transparency that is actually more straightforward than the opaque negotiated rate structures of insurance-based medicine, but only when clinics handle pricing honestly.
Before committing to any procedure, patients should receive a written, itemized cost breakdown that covers the consultation, laboratory processing of cells, the procedure itself, any imaging guidance, and the follow-up appointment. Any clinic that is unwilling to provide this level of price transparency in writing before you commit deserves scrutiny. Legitimate clinics state their fees clearly.
Watch for pricing structures that bundle services in ways that make it difficult to understand what you are paying for. Ask specifically: what happens if the cell collection yield is insufficient? What happens if you need a second injection? Is there a charge for that? Are follow-up visits included in the initial fee or billed separately? These are reasonable questions that any well-run clinic should answer directly.
Financing Options Clinics Commonly Offer
Many regenerative medicine clinics partner with medical financing companies to give patients access to payment plans. The most common financing options in this space include CareCredit and Alphaeon Credit, both of which are specialty medical financing products with promotional interest-free periods. Some clinics also offer in-house payment arrangements.
When evaluating a financing offer, patients should review the actual interest rate that applies after any promotional period ends, the total term of the loan, what happens if you need to reschedule or if treatment needs to be modified, and whether there are prepayment penalties. Medical financing at 0% interest during a promotional window is a reasonable tool for managing a cash-pay expense, but the same product can become expensive if the balance is not paid before the promotional period expires and deferred interest applies.
Financing exists because regenerative procedures represent a meaningful out-of-pocket expense for most patients. Using it responsibly means understanding the full terms, not just the monthly payment amount.
HSA and FSA Applicability
Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) allow accountholders to use pre-tax dollars for qualified medical expenses as defined by the IRS under Section 213 of the Internal Revenue Code. The key question for regenerative medicine is whether a specific procedure qualifies.
Research and clinical guidance from HSA administrators suggests that stem cell therapy and PRP administered to treat a diagnosed medical condition may qualify as a qualified medical expense. The treatment must be directed at diagnosing, treating, mitigating, or preventing a specific disease or condition, not at general health or wellness. A patient receiving stem cell injections for documented knee osteoarthritis has a stronger basis for HSA or FSA use than one receiving treatment for non-specific pain without a formal diagnosis.
A Letter of Medical Necessity from the treating physician significantly strengthens the documentation for HSA or FSA reimbursement. This letter typically includes the patient’s diagnosis, the physician’s clinical rationale for the treatment, and the expected duration of treatment. Most HSA and FSA administrators will process reimbursements for procedures supported by an LMN and a valid diagnosis code. Patients should always consult with their HSA or FSA plan administrator and their tax advisor before assuming a specific treatment qualifies, as the IRS rules and individual plan terms can affect eligibility.
What to Ask Your Clinic and Your Insurer
How to Get a Pre-Authorization Inquiry in Writing
Before committing financially to a regenerative procedure, call your insurance company directly to ask whether any regenerative therapies are covered under your specific plan. This is not a guarantee of coverage, but it is a reasonable first step.
Ask specifically: does my plan cover intra-articular biologic injections, PRP, or autologous cell therapies for musculoskeletal conditions? What diagnostic codes and procedure codes would I need to provide? Is there a pre-authorization process I should follow?
Request that any response confirming or denying coverage be provided in writing, either through a formal coverage determination letter or a written summary of the phone interaction including the representative’s name and the date. Understand that a response of “not currently denied” is not the same as a pre-authorization or a guarantee of coverage. Pre-authorization is also not a guarantee of payment after the fact – it is a statement of intent based on information available at the time of the inquiry.
What to Document for Potential Future Reimbursement
Some patients submit for insurance reimbursement after a procedure, particularly as the evidence base for regenerative medicine grows and as coverage policies shift. Even if reimbursement is unlikely now, thorough documentation creates a record that may be useful in the future.
Keep the following documentation: an itemized receipt from the clinic showing the specific services rendered, the associated diagnosis codes (ICD-10), the procedure codes submitted, a letter from your physician explaining the medical necessity of the treatment, and any prior authorization communications with your insurer.
The landscape of coverage for regenerative medicine is not static. As clinical trial data accumulates and as FDA pathways for specific cell therapy products advance, insurers will face increasing pressure to update their coverage determinations. Patients who maintain clear documentation of their treatments, clinical rationale, and outcomes contribute to that evidence base in a practical way.
Sources
- FDA Framework for Regulation of Regenerative Medicine Products
- CMS Local Coverage Determination: Platelet Rich Plasma Injections for Non-Wound Indications (L39058)
- CMS National Coverage Determination: Autologous Platelet-rich Plasma
- Ninth Circuit Confirms Certain Stem Cell Products Require FDA Premarket Approval (Cooley Law)
- Regenerative Medicine Advanced Therapy (RMAT) Designation – FDA
- Four FDA Draft Guidance Documents and the REGROW Act: HCT/P Regulatory Policy – PMC
Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.